Sugi Predict

Sugi Predict / Compounds / SCHEMBL6407514

SCHEMBL6407514

SCHEMBL6407514

COc1ccc(CN2C(=O)CNC2=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.64
▸ KMT2A Q03164 4/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ MAPT P10636 1/20 0.64
▸ GSK3A P49840 3/20 0.63
▸ GSK3B P49841 3/20 0.63
▸ CMA1 P23946 1/20 0.62
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ BLM P54132 1/20 0.56
▸ GAA P10253 3/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CASP3 P42574 2/20 0.51
▸ APAF1 O14727 1/20 0.51
▸ SENP8 Q96LD8 1/20 0.51
▸ SENP7 Q9BQF6 1/20 0.51
▸ SENP6 Q9GZR1 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29304536 0.86 CMA1 (0.57) MEN1KMT2AALDH1A1MAPTGSK3A
SCHEMBL12615721 0.84 GSK3A (0.60) MEN1KMT2AALDH1A1MAPTGSK3A
SCHEMBL23120576 0.84 MEN1 (0.61) MEN1KMT2AALDH1A1MAPTGSK3A
Hydrochloric Acid SCHEMBL30616170 0.83 MEN1 (0.59) MEN1KMT2AALDH1A1MAPTGSK3A
SCHEMBL8320050 0.81 SMN1; SMN2 (0.73) MEN1KMT2AALDH1A1MAPTGSK3A
SCHEMBL26098144 0.80 KMT2A (0.63) MEN1KMT2AALDH1A1GSK3AGSK3B
SCHEMBL6668852 0.80 L3MBTL1 (0.56) MEN1KMT2AALDH1A1MAPTGSK3A
SCHEMBL23142734 0.80 MEN1 (0.59) MEN1KMT2AALDH1A1MAPTGSK3A
SCHEMBL6525579 0.80 L3MBTL1 (0.56) MEN1KMT2AALDH1A1MAPTGSK3A
SCHEMBL6293317 0.80 KMT2A (0.73) MEN1KMT2AALDH1A1MAPTGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4585265-A2 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2025-07-16 — — EP disclosed
EP-4558485-A1 TEAD INHIBITORS AND METHODS OF USE Sporos Biodiscovery, Inc. (US) 2025-05-28 — — EP disclosed
CN-119497708-A TEAD inhibitors and methods of use 思博睿生物探索公司 2025-02-21 — — CN disclosed
US-20240368153-A1 Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors Mirati Therapeutics, Inc. 2024-11-07 — — US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 — — US disclosed
US-RE49934-E1 Inhibitors of cellular metabolic processes SERVIER PHARMACEUTICALS LLC (US) 2024-04-23 — — US disclosed
WO-2024020350-A1 TEAD INHIBITORS AND METHODS OF USE SPOROS BIODISCOVERY, INC. (US) 2024-01-25 — — WO disclosed
EP-4308230-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 — — EP disclosed
US-8816079-B2 Amide derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-08-26 — — US disclosed
CN-102971291-A Novel amide derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORP 2013-03-13 — — CN disclosed
EP-2565182-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2013-03-06 — — EP disclosed
US-20130040930-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-02-14 — — US disclosed
US-20130040930-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-02-14 — — US disclosed
US-20130040930-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-02-14 — — US disclosed
US-20080119419-A1 Bifunctional heterocyclic compounds and methods of making and using same BioVersys AG (CH) 2008-05-22 — — US disclosed
US-20070072811-A1 Bifunctional heterocyclic compounds and methods of making and using the same RIB-X PHARMACEUTICALS, INC. 2007-03-29 — — US disclosed
EP-1534696-A1 THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS Merck & Co., Inc. (US) 2005-06-01 — — EP disclosed
WO-2004011448-A1 THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS MERCK & CO., INC. (US) 2004-02-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119419-A1 Bifunctional heterocyclic compounds and methods of making and using same PCNA, DCX, ATIC MEN1 448/4885KMT2A 4043/4885ALDH1A1 2559/4885
US-20070072811-A1 Bifunctional heterocyclic compounds and methods of making and using the same PCNA, DCX, HPGDS MEN1 581/4885KMT2A 4064/4885ALDH1A1 2456/4885
US-20130040930-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 MEN1 2998/4885KMT2A 685/4885ALDH1A1 594/4885
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 MEN1 1290/4885KMT2A 1222/4885ALDH1A1 3026/4885
US-20240368153-A1 Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors PRMT5, PRMT1, PRMT3 MEN1 1250/4885KMT2A 85/4885ALDH1A1 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.